A Time to Ignore “No Meat, No Treat”

Restaging computed tomography scans of the chest/abdomen/pelvis are needed to assess extracranial disease  burden and determine whether there is an accessible lesion for biopsy (if systemic therapy will be considered).1 Furthermore, this serves to rule out the potential of another primary that may warrant whole-brain radiation therapy consideration (ie, small cell lung cancer).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research

Related Links:

Conclusions: Crizotinib was effective and well tolerated in Chinese patients with ALK-positive, advanced NSCLC in real-world clinical practice. For patients without BBM, crizotinib as first-line therapy can lead to a longer PFS than second-or later line therapy. CBPD plus local therapy after 1st PD beyond crizotinib is feasible and effective in clinical routine practice.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Sano M, Kaneko MK, Kato Y Abstract The highly O-glycosylated membrane glycoprotein podoplanin (PDPN) is frequently overexpressed in several malignant cancers, such as oral cancer, lung cancer, germinal neoplasia, mesothelioma, and brain tumor. The expression of PDPN is strongly associated with cancer progression and poor prognosis. PDPN possesses three tandem repeats of platelet aggregation-stimulating (PLAG) domains (PLAG1, PLAG2, and PLAG3) and PLAG-like domain (PLD), and binds to C-type lectin-like receptor 2 (CLEC-2) on platelets, followed by PDPN-mediated platelet aggregation. We have previously estab...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors have been developed for the treatment of EML4-ALK-rearranged non-small-cell lung cancer, with the newer generation agents brigatinib, alectinib and lorlatinib showing pronounced central nervous system activities. Intracranial efficacy is an important feature for these agents, as metastatic lesions frequently occur in the central nervous system in the ALK-positive setting. Here, we report on an updated case of a patient who received her diagnosis in 2005 and has had disease progression with new lesions on six occasions over the last 8 years. During the firs...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
ConclusionsThe efficacy of crizotinib in patients with advanced NSCLC is related to the number of metastatic organs, age and timing of treatment. The use of crizotinib is prone to intracranial progression, and progression of simple brain metastases is not an indication that crizotinib is discontinued. Patients will continue to benefit from combination of local radiotherapy.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, whom received apatinib (250mg or 500mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second- or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rat...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Publication date: Available online 15 October 2019Source: The Lancet Respiratory MedicineAuthor(s): Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang WuSummaryBackgroundEnsartinib is a potent new-generation ALK inhibitor with high activity against a broad range of known crizotinib-resistant ALK mutations and CNS metastases. We aimed to assess the efficacy and safety of ensartinib in ALK-positive patients with non-small-cell lung cancer (NSCLC), i...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
We describe here a case of 48 y.o. male patient with ALK-positive NSCLC who was clinically managed for 6.5 years from the diagnosis. The tumor was surgically resected, but 8 months later multiple brain metastases were discovered. The patient started receiving platinum-based chemotherapy and then was enrolled in a clinical trial of second-generation ALK inhibitor ceritinib, which resulted in a 21 months stabilization. Following disease relapse, the patient was successfully managed for 33 months with different lines of chemo- and local ablative therapies. Chemotherapy regimens, including off-label combination of crizotinib +...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract Traditional cancer therapies, such as treatment with anthracyclines and chest radiation, are known to induce cardiovascular complications. Currently, the increase of cancer therapies will involve new mechanisms such as cancer immunotherapies, also called immune checkpoint inhibitors (PD-1, PD-L1 and CTLA-4 inhibitors). These treatments have shown long-term remissions in subgroup of cancers, including melanomas, non-small-cell lung cancer, urothelial carcinoma, renal cell carcinoma, squamous cell carcinoma of the head and neck and colorectal cancer. Although these treatments will change the natural course ...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality around the world. Brain metastasis (BM) is seen in up to 20-40% patients with NSCLC [1,2]. Patients with EGFR mutation have a higher likelihood of BM because of prolonged survival by EGFR tyrosine kinase inhibitors (EGFR-TKIs) [3 –5]. Further, whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) and surgical excision are options for local control, and each shows different treatment benefit in selected subgroups [6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
BOSTON (AP) — Everybody seems to be having fun when the kids in a new public service announcement are just playing football, until one boy is thrown to the ground and the background music turns ominous. Then, the coach starts handing out cigarettes. “Tackle football is like smoking,” a youthful voice-over says as a smiling, motherly type lights a cigarette for one of the pre-teen players. “The younger I start, the longer I’m exposed to danger.” “Tackle Can Wait ” is part of a campaign by the Boston-based Concussion Legacy Foundation to steer children under 14 years old into f...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Concussion Legacy Foundation Concussions Youth Football Source Type: news
More News: Biology | Brain | Brain Cancers | Cancer | Cancer & Oncology | CT Scan | Lung Cancer | Meat | Neurology | PET Scan | Physics | Radiation Therapy | Radiology